Ardent Health (ARDT) to Post Quarterly Earnings on Tuesday

Ardent Health (NYSE:ARDT) is anticipated to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Ardent Health to post earnings of $0.17 per share and revenue of $1.5897 billion for the quarter. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Ardent Health (NYSE:ARDT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.10. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Ardent Health had a return on equity of 13.85% and a net margin of 2.09%. On average, analysts expect Ardent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Ardent Health Stock Up 3.4%

NYSE ARDT traded up $0.38 during trading on Tuesday, reaching $11.32. 63,414 shares of the company’s stock were exchanged, compared to its average volume of 456,786. The stock has a market cap of $1.62 billion, a P/E ratio of 11.93, a price-to-earnings-growth ratio of 2.50 and a beta of 0.76. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.00 and a current ratio of 2.12. The company has a 50 day moving average price of $9.67 and a two-hundred day moving average price of $9.36. Ardent Health has a 1 year low of $7.71 and a 1 year high of $15.48.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ARDT shares. Truist Financial cut their target price on Ardent Health from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ardent Health in a report on Friday, June 12th. UBS Group increased their price target on shares of Ardent Health from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada cut their price objective on shares of Ardent Health from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Ardent Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $14.04.

Insider Buying and Selling

In other news, CFO Alfred Lumsdaine purchased 10,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were bought at an average price of $8.81 per share, with a total value of $88,100.00. Following the completion of the transaction, the chief financial officer directly owned 329,183 shares in the company, valued at approximately $2,900,102.23. This represents a 3.13% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ardent Health

Several large investors have recently modified their holdings of ARDT. Prelude Capital Management LLC grew its position in shares of Ardent Health by 30.3% during the third quarter. Prelude Capital Management LLC now owns 18,303 shares of the company’s stock worth $243,000 after acquiring an additional 4,259 shares during the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in Ardent Health in the 4th quarter valued at $238,000. VARCOV Co. acquired a new stake in Ardent Health during the 4th quarter worth $232,000. Wells Fargo & Company MN boosted its stake in Ardent Health by 29.1% during the 4th quarter. Wells Fargo & Company MN now owns 25,963 shares of the company’s stock worth $229,000 after purchasing an additional 5,858 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Ardent Health during the 4th quarter worth $228,000.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.